XML 48 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2024
Mar. 31, 2024
Oct. 31, 2023
Sep. 30, 2022
Nov. 30, 2021
Mar. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2019
Jun. 30, 2022
Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss $ 238           $ 238 $ 129        
Inventory Valuation Reserves 605           605 76        
Payments to Acquire Intangible Assets             9,988 775 $ 2,750      
Finite-Lived Intangible Assets, Accumulated Amortization 2,381           2,381 1,286        
Amortization of Intangible Assets             1,096 790 1,617      
Impairment, Long-Lived Asset, Held-for-Use             0 0 0      
Finance Lease, Liability 0           $ 0 $ 0        
Percentage for Valuation Reserve Against Deferred Tax Assets             100.00% 100.00%        
Unrecognized Tax Benefits 382           $ 382 $ 0 $ 0     $ 0
Unrecognized Tax Benefits that Would Impact Effective Tax Rate $ 0           0 0        
Carglumic Acid Product Rights [Member]                        
Payments to Acquire Intangible Assets         $ 3,250              
Finite-Lived Intangible Asset, Useful Life (Year)         10 years              
Biorphen [Member]                        
Payments to Acquire Intangible Assets                   $ 750    
Finite-Lived Intangible Asset, Useful Life (Year)                   5 years    
Finite-Lived Intangible Assets, Accumulated Amortization                     $ 275  
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year               $ 75        
Rezipres Product [Member]                        
Payments to Acquire Intangible Assets           $ 750            
Finite-Lived Intangible Asset, Useful Life (Year)           5 years            
Finite-Lived Intangible Assets, Accumulated Amortization                     $ 738  
Betaine Anhydrous Product Rights [Member]                        
Payments to Acquire Intangible Assets       $ 2,125                
Finite-Lived Intangible Asset, Useful Life (Year)       5 years                
Nitisinone Product Rights [Member]                        
Payments to Acquire Intangible Assets     $ 650                  
Finite-Lived Intangible Asset, Useful Life (Year)     5 years                  
PKU GoLike [Member]                        
Payments to Acquire Intangible Assets   $ 1,868                    
Finite-Lived Intangible Asset, Useful Life (Year)   10 years                    
Increlex [Member]                        
Payments to Acquire Intangible Assets             $ 21,250          
Finite-Lived Intangible Asset, Useful Life (Year) 10 years           10 years          
GALZIN [Member]                        
Payments to Acquire Intangible Assets $ 8,119                      
Finite-Lived Intangible Asset, Useful Life (Year) 10 years           10 years          
Furniture and Fixtures [Member]                        
Property, Plant and Equipment, Useful Life (Year) 5 years           5 years          
Increlex [Member]                        
Inventory, Raw Materials, Gross $ 5,000           $ 5,000          
Product Concentration Risk [Member] | Revenue Benchmark [Member] | AnovoRx [Member]                        
Concentration Risk, Percentage             93.60% 78.20% 45.50%      
Customer Concentration Risk [Member] | Accounts Receivable [Member] | AnovoRx [Member]                        
Concentration Risk, Percentage             96.20% 97.40%